Algeta ASA
oslo : ALGETA

May 14, 2013 01:08 ET

Algeta to Participate in Upcoming Investor Conferences

OSLO, NORWAY--(Marketwired - May 14, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and investor relations teams will participate in the following upcoming investor conferences:

Bank of America Merrill Lynch Healthcare Conference

     Date: 13-16 May 2013

     Participants:

         Mike Booth (SVP, Communications)

     Presentation date & time: Thursday 16 May, 2013, 12:00 noon PDT

     Venue: Las Vegas, NV, USA


 UBS Global Life Science Conference

     Date: 20-22 May 2013

     Participants:

         Mike Booth (SVP, Communications)

     Presentation date & time: Monday 20 May, 2013, 8:30am EDT

     Venue: New York City, NY, USA


 BioEquity Europe 2013

     Date: 22-23 May 2013

     Participants:

         Mike Booth (SVP, Communications)

         Renate Birkeli (IR)

     Presentation date & time: Wednesday 22 May, 2013, 3:00pm CET

     Venue: Stockholm, Sweden


 Deutsche Bank Healthcare Conference

     Date: 29-30 May 2013

     Participants:

         Andrew Kay (President & CEO)

         Mike Booth (SVP, Communications)

     Presentation date & time: Thursday 30 May, 2013, 11:20am EDT

     Venue: Boston, MA, USA


 Jefferies Global Healthcare Conference

     Date: 3-6 June 2013

     Participants:

         Gillies O'Bryan-Tear (Chief Medical Officer)

         Mike Booth (SVP, Communications)

     Presentation date & time: Tuesday 4 June, 2013, 3:30pm EDT

     Venue: New York City, NY, USA


 Goldman Sachs Healthcare Conference

     Date: 11-13 June 2013

     Participants:

         Jeff Albers (President, Algeta US)

         Mike Booth (SVP, Communications)

     Presentation date & time: Wednesday 12 June, 2013, 8:40am PDT

     Venue: Palos Verdes, CA, USA

Presentations, where applicable, will be available to download at www.algeta.com following these events.

###

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

Algeta to Participate in Upcoming Investor Conferences: http://hugin.info/134655/R/1701405/561725.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1701405]

Contact Information

  • For further information, please contact:

    Mike Booth / Renate Birkeli
    +47 23 00 67 32
    Communications & Corporate Affairs
    Email Contact

    Media enquiries:
    Mark Swallow
    +44 207 638 9571
    Citigate Dewe Rogerson
    Email Contact

    Knut Ekern
    +47 22 04 82 00
    Gambit Hill & Knowlton
    Email Contact

    Kari Watson
    +1 781 235 3060
    MacDougall Biomedical Communications
    Email Contact

    US investor enquiries:
    Tricia Swanson
    +1 646 378 2953
    The Trout Group
    Email Contact